Wall Street analysts predict that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will report $493.63 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for IDEXX Laboratories’ earnings, with the highest sales estimate coming in at $499.90 million and the lowest estimate coming in at $490.40 million. IDEXX Laboratories reported sales of $448.31 million in the same quarter last year, which indicates a positive year-over-year growth rate of 10.1%. The business is expected to report its next quarterly earnings report before the market opens on Tuesday, October 31st.

According to Zacks, analysts expect that IDEXX Laboratories will report full-year sales of $493.63 million for the current fiscal year, with estimates ranging from $1.95 billion to $1.96 billion. For the next year, analysts forecast that the company will report sales of $2.14 billion per share, with estimates ranging from $2.10 billion to $2.17 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for IDEXX Laboratories.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.10. The firm had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.74 earnings per share.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus restated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Wednesday, August 2nd. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Canaccord Genuity restated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Bank of America Corporation upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a research note on Wednesday, August 23rd. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $174.00.

Shares of IDEXX Laboratories (NASDAQ:IDXX) opened at 164.71 on Monday. The firm has a market cap of $14.38 billion, a PE ratio of 56.66 and a beta of 0.48. IDEXX Laboratories has a 52-week low of $102.45 and a 52-week high of $173.01. The company’s 50-day moving average price is $158.19 and its 200-day moving average price is $160.18.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $493.63 Million” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/10/23/zacks-brokerages-anticipate-idexx-laboratories-inc-idxx-will-announce-quarterly-sales-of-493-63-million.html.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the transaction, the chairman now directly owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the completion of the transaction, the chief executive officer now directly owns 1,043,034 shares in the company, valued at $161,576,396.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 151,734 shares of company stock worth $23,436,626. Insiders own 2.77% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in IDXX. APG Asset Management N.V. increased its holdings in shares of IDEXX Laboratories by 150.5% during the third quarter. APG Asset Management N.V. now owns 215,200 shares of the company’s stock worth $33,461,000 after purchasing an additional 129,300 shares during the period. Denali Advisors LLC increased its holdings in shares of IDEXX Laboratories by 1,766.7% during the third quarter. Denali Advisors LLC now owns 28,000 shares of the company’s stock worth $4,354,000 after purchasing an additional 26,500 shares during the period. LS Investment Advisors LLC increased its holdings in shares of IDEXX Laboratories by 8.2% during the third quarter. LS Investment Advisors LLC now owns 4,846 shares of the company’s stock worth $754,000 after purchasing an additional 368 shares during the period. Oakbrook Investments LLC increased its holdings in shares of IDEXX Laboratories by 27.0% during the third quarter. Oakbrook Investments LLC now owns 4,230 shares of the company’s stock worth $658,000 after purchasing an additional 900 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its holdings in shares of IDEXX Laboratories by 4.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 157,021 shares of the company’s stock worth $24,416,000 after purchasing an additional 7,176 shares during the period. 87.58% of the stock is currently owned by institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Get a free copy of the Zacks research report on IDEXX Laboratories (IDXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.